Exactly! Plus a BP would be better able to conduct the studies that they
believe would increase the exclusivity period. Imagine how many various
health issues could be studied with the appropriate trials that would
result in further exclusivity time. (I wonder if there is an absolute
limit?) Regardless, a Eurocentric BP is in a much stronger position to
make Vazkepa into the Mega-Blockbuster drug it should be.
With regard to the US, if a BP acquired AMRN, they may decide to come
out with their own authorized generic by rebranding it and relaunching
it under their own "flag" complete with a brand new advertising
campaign. (I would love for Pfizer to be the buyer as they are
the in the best position to capitalize on their stellar reputation.)
That by itself could make all the difference...going from a company
(Amarin) that nobody has ever heard of...to a company that everyone
knows provided the best Covid vaccine according to most.
News 
Market Data 
Discover 
AI
